Resolute Advisors LLC Makes New $225,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Resolute Advisors LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 9,289 shares of the company's stock, valued at approximately $225,000.

A number of other large investors also recently bought and sold shares of the stock. Crewe Advisors LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HIMS. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Morgan Stanley cut Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price target for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. BTIG Research started coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Bank of America boosted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and an average target price of $37.31.

Remove Ads

Insider Buying and Selling

In other news, insider Michael Chi sold 7,259 shares of the business's stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $24.07, for a total value of $174,724.13. Following the completion of the sale, the insider now owns 193,601 shares of the company's stock, valued at approximately $4,659,976.07. The trade was a 3.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Irene Becklund sold 2,203 shares of Hims & Hers Health stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now directly owns 8,007 shares of the company's stock, valued at approximately $230,441.46. This represents a 21.58 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 809,806 shares of company stock valued at $30,923,658. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Down 2.2 %

Shares of HIMS stock traded down $0.57 during trading hours on Wednesday, hitting $25.53. 8,542,069 shares of the company were exchanged, compared to its average volume of 14,847,568. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The firm has a fifty day moving average of $39.53 and a 200 day moving average of $30.15. The firm has a market cap of $5.67 billion, a PE ratio of 57.98 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.